The defendants allegedly claimed that their Geniux products can improve short and long-term memory, increase focus by as much as 300 percent, prevent memory loss, and boost IQ. Additionally, they allegedly claimed that the Geniux products had been tested in more than 2,000 clinical trials. However, all these claims are false, a violation of the FTC Act.
According to the Commission, the defendants agreed to settle the charges against them. They agreed to stop their wrongdoing and to pay financial penalties.
In a statement, Andrew Smith, Director, Bureau of Consumer Protection at FTC, commented, “With an aging population, it is more important than ever that advertisers have solid evidence to back up their claims about memory and cognitive health benefits.”
“Moreover, the FTC will hold companies accountable when they deceptively design their ads to look like news articles and fabricate celebrity endorsements and consumer testimonials,” said Smith.
